Pfizer announces Executive Leadership Team
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced its executive team that will report to Albert Bourla, incoming Chief Executive Officer, coincident with the commencement of his new role effective January 1, 2019.
Sandoz Healthcare Access Challenge #SandozHACk returns, seeking digital solutions to local healthcare access challenges
- Details
- Category: Novartis
Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global competition that invites entrepreneurs and innovators in the field of digital technology to submit inspirational ideas with the potential to complement - or even positively disrupt - established approaches to driving access to healthcare.
Pfizer to award more than $3 million in grants to further breast cancer research
- Details
- Category: Pfizer
Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants totaling more than $3 million (USD) in funding will be awarded to investigators in the United States (U.S.) to support clinical research projects involving Pfizer compounds in breast cancer.
Sanofi completes divestiture of Zentiva to Advent
- Details
- Category: Sanofi
Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The transaction was finalized ahead of schedule for €1,9 billion (enterprise value).
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
- Details
- Category: Novartis
Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates that are part of the Novartis Infectious Diseases portfolio, which have the potential to address the need for new agents to treat antibiotic resistant Gram-negative infections.
Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention
- Details
- Category: Novo Nordisk
New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.(1) Researchers linked factors such as food traditions and traditional gender roles to increasing vulnerability to diabetes in cities(1), where three-quarters of people with the disease are set to live by 2045.(3)
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
- Details
- Category: Boehringer Ingelheim
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC).
More Pharma News ...
- Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
- The Merck Accelerator Program 2019
- Novo Nordisk announces plans to transform its approach to Research & Development
- World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
- The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
- Abbott is named global industry leader in sustainability for the sixth consecutive year on the Dow Jones Sustainability Index (DJSI)
- Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis